AXONIS THERAPEUTICS, INC.

Axonis Therapeutics is a Boston-based, neuro-focused biotechnology company developing first- and best-in-class medicines targeting KCC2, a critical mediator of inhibition within the brain. The company translates breakthrough discoveries spun out from Boston Children's Hospital, Harvard, and Laval University into oral therapeutics for currently incurable neurological disorders including pain, epilepsy, and psychiatric conditions. Axonis raised $115M in a Series A round in October 2024 to fund Phase I clinical trials.